ACE-inhibitors: Be aware of the distinction between bradykinin- and histamine-mediated angioedema, as treatment strategies differ significantly
Authored by Medicines and Healthcare products Regulatory Agency (MHRA)Originally published 16 Jun 2026
Meets Patient’s editorial guidelines
- DownloadDownload
- Share
- Language
- Discussion
- Ask Patient
- Audio Version
- Add to preferred sources on Google
Medical Professionals
Professional Reference articles are designed for health professionals to use. They are written by UK doctors and based on research evidence, UK and European Guidelines. You may find one of our health articles more useful.
Healthcare professionals should be aware of the potential for delayed onset of angioedema and the distinction between bradykinin- and histamine-mediated cases, as treatment strategies differ significantly and bradykinin-medi…
Read the full update from MHRA
About MHRA alerts and recalls
The Medicines and Healthcare products Regulatory Agency (MHRA) is the UK’s regulator for medicines, vaccines and medical devices. One of its key responsibilities is to monitor the safety and effectiveness of products in use across the NHS and wider healthcare system. When new safety concerns are identified, or when issues arise with the manufacture or distribution of a medicine or device, the MHRA issues alerts and recalls to protect patients and support healthcare professionals.
These alerts can take several forms. Some provide updated guidance on prescribing or monitoring requirements for medicines and vaccines. Others may highlight newly recognised side effects, or remind clinicians of important risk-mitigation steps. In the case of medical devices, alerts may cover field safety notices, product recalls, or urgent device modifications. All of these communications are designed to ensure that products are used safely and that any risks are managed appropriately.
Patient.info republishes MHRA alerts and recalls so that this information is available quickly and accessibly to both healthcare professionals and the public. The summary above is taken directly from the MHRA’s official publication. To read the full advice, including detailed recommendations for prescribers, manufacturers and patients, please follow the “Read more” link to the MHRA website.
If you are a healthcare professional, you should consult the full notice to confirm the latest prescribing information, monitoring requirements and any actions you need to take in your practice. If you are a patient or carer, do not stop treatment or make changes to your medication or device without first seeking professional advice. If you have any concerns about your medicine or device, speak to your GP, pharmacist or specialist nurse.
Contains public sector information licensed under the Open Government Licence v3.0.
Patient picks for Alerts, recalls and safety information

Professional
Assessment of the patient with established diabetes
Each visit can be viewed as an opportunity to assess and improve the patient's understanding of their illness, and their ability to control the disease. This article provides a summary of the areas of assessment relevant to type 1 diabetes and type 2 diabetes, which will need to be adapted, depending on an individual patient's type of diabetes..
by Dr Toni Hazell, FRCGP

Professional
Laryngitis
Accurate information of the epidemiology of acute laryngitis is uncert... Thibeault SL, Rees L, Pazmany L, et al; At the crossroads: mucosal immunology of the larynx. Epub 2009 Jan 7. 26980 : At the crossroads: mucosal immunology of the larynx. Medication such as: Huntzinger A; Guidelines for the diagnosis and management of hoarseness, American.
by Dr Colin Tidy, MRCGP

Professional
Diabetes and hypertension
This article aims to provide a simple management plan for the management of people with diabetes mellitus who also have raised blood pressure (BP). It is based mainly on the current National Institute for Health and Care Excellence (NICE) recommendations. See also the Hypertension Hypertension and Hypertension treatment Hypertension treatment.
by Dr Philippa Vincent, MRCGP
/og.png)
Professional
Update 1 - Nestlé recalls several SMA Infant Formula and Follow-On Formula as a precaution because of the possible presence of cereulide (toxin)
Nestlé has updated the precautionary recall of several SMA Infant Formula and Follow-On Formula because they may contain cereulide toxin. Read the full update from FAS About FSA food safety alerts and recalls The Food Standards Agency (FSA) is responsible for food safety and food hygiene across the UK. One of its key roles is to monitor risks.
by Food Standards Agency (FSA)
%3A%20Consider%20delayed%20administration%20of%20concurrent%20echinocandins%2C%20such%20as%20caspofungin%2C%20to%20reduce%20the%20risk%20of%20adsorption%20onto%20new%20polyacrylonitrile%20(PAN)-based%20filter%20membranes%20DSI%2F2026%2F014/og.png)
Professional
Continuous renal replacement therapy (CRRT): Consider delayed administration of concurrent echinocandins, such as caspofungin, to reduce the risk of adsorption onto new polyacrylonitrile (PAN)-based filter membranes DSI/2026/014
Continuous renal replacement therapy (CRRT) is used for managing severe acute kidney injury and fluid overload. Read the full update from MHRA About MHRA alerts and recalls The Medicines and Healthcare products Regulatory Agency (MHRA) is the UK’s regulator for medicines, vaccines and medical devices. One of its key responsibilities is to monit....
by Medicines and Healthcare products Regulatory Agency (MHRA)

Medicine
Moexipril - an ACE inhibitor
The first dose of moexipril may make you feel dizzy, so it is best taken just before bedtime. Some painkillers and indigestion remedies interfere with moexipril, so ask your pharmacist for advice before you buy any medicines. Some people taking moexipril can develop a troublesome cough. If this happens to you, let your doctor know.
by Michael Stewart, MRPharmS
Exclusive updates for healthcare professionals
Stay informed with the latest clinical updates, professional insights, and evidence-based guidance. The Patient Pro newsletter curates essential content for healthcare professionals—delivered straight to your inbox.
By subscribing you accept our Privacy Policy. You can unsubscribe at any time. We never sell your data.
Article history
Article also available in English, German, Spanish, French, Italian, Portuguese, Hindi, Hebrew, Arabic, and Swedish.
16 Jun 2026 | Originally published
Authored by:
Medicines and Healthcare products Regulatory Agency (MHRA)
More in alerts, recalls and safety information
- NewClass 2 Medicines Recall: Advanz Pharma Limited, Mynzepli 40 mg/mL solution for injection in pre-filled syringe, EL(26)A/44
- Class 2 Medicines Recall: Amarox Limited, Sertraline 100mg film-coated tablets, EL(26)A/22
- Class 3 Medicines Recall: Flamingo Pharma UK Ltd, Flucloxacillin Capsules BP 500mg, EL(26)A/32
- Class 4 Medicines Defect Notification: Brancaster Pharma Limited, Benzylpenicillin benzathine 1.2 Million I.U. and 2.4 Million I.U. powder for suspension for injection, EL(26)A/30
- Class 4 Medicines Defect Notification: Cadila Pharmaceuticals Limited, Mirtazapine 30mg Tablets, EL(26)A/28
- Class 4 Medicines Defect Notification: Milpharm Limited, Loperamide hydrochloride 2 mg Orodispersible Tablets, EL(26)A/23
- NewClass 4 Medicines Defect Notification: Sandoz Limited, Co-Amoxiclav powder for oral suspension 250/62.5 mg/mL, EL(26)A/46
- Class 4 Medicines Defect Notification: Teva UK Ltd, Ponlimsi (Denosumab) 60mg Solution for Injection in Pre-filled Syringe, EL(26)A/27
- Field Safety Notices: 1 May 2026
- Field Safety Notices: 5 to 9 October 2026
- Field Safety Notices: 17 to 21 November 2025
- NewField Safety Notices: 19 to 23 October 2026
- Field Safety Notices: 27 to 31 July 2026
- Field Safety Notices: 29 June to 03 July 2026
- Field Safety Notices: 31 August to 4 September 2026
- MHRA Safety Roundup: April 2026
- MHRA Safety Roundup: July 2026
- MHRA Safety Roundup: June 2026
- NewMHRA Safety Roundup: October 2026


